Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 337.50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.37 per share when it actually produced earnings of $0.23, delivering a surprise of 162.16%.Over the ...

Company Performance - Akebia Therapeutics reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, and showing improvement from a loss of $0.09 per share a year ago, resulting in an earnings surprise of 200% [1] - The company posted revenues of $57.34 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 26.83%, compared to year-ago revenues of $32.61 million [2] - Over the last four quarters, Akebia has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Stock Performance - Akebia Therapeutics shares have increased approximately 29.5% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $44.05 million, and for the current fiscal year, it is -$0.12 on revenues of $192.75 million [7] Industry Outlook - The Medical - Drugs industry, to which Akebia belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Group 1 - Stratasys reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, compared to a loss of $0.02 per share a year ago, representing an earnings surprise of 33.33% [1] - The company posted revenues of $136.05 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.84%, but down from $144.05 million year-over-year [2] - Stratasys shares have increased approximately 9.3% since the beginning of the year, while the S&P 500 has declined by 4.3% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $0.05 on revenues of $137.88 million, and for the current fiscal year, it is $0.29 on revenues of $566.23 million [7] - The Commercial Printing industry, to which Stratasys belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] Group 3 - Stratasys has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates two times in the same period [2] - The estimate revisions trend for Stratasys is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6]

The Real Brokerage Inc. (REAX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 60%. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.03, delivering a surprise of 40%.Over the last four quarters, the company has surpas ...

Warner Bros. Discovery (WBD) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this operator of cable TV channels such as TLC and Animal Planet would post earnings of $0.04 per share when it actually produced a loss of $0.20, delivering a surprise of -6 ...

Viatris (VTRS) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.04%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.57 per share when it actually produced earnings of $0.54, delivering a surprise of -5.26%.Over the last four quarters, the company ...

Core Insights - Xeris Biopharma reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.07, and improved from a loss of $0.14 per share a year ago, representing an earnings surprise of 14.29% [1] - The company achieved revenues of $60.12 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 4.76% and up from $40.64 million year-over-year [2] - Xeris Biopharma's stock has increased by approximately 32.2% since the beginning of the year, contrasting with a decline of -4.3% in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $63.36 million, and for the current fiscal year, it is -$0.11 on revenues of $264.52 million [7] - The estimate revisions trend for Xeris Biopharma is favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Xeris Biopharma belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Another company in the same industry, Zevra Therapeutics, is expected to report a quarterly loss of $0.21 per share, with revenues anticipated to be $15.8 million, reflecting a significant year-over-year increase of 360.6% [9][10]

Group 1 - International Seaways reported quarterly earnings of $0.80 per share, exceeding the Zacks Consensus Estimate of $0.59 per share, but down from $2.92 per share a year ago, representing an earnings surprise of 35.59% [1] - The company posted revenues of $183.39 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.17%, compared to year-ago revenues of $274.4 million [2] - International Seaways has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] Group 2 - The stock has added about 1.1% since the beginning of the year, while the S&P 500 has declined by 4.3% [3] - The current consensus EPS estimate for the coming quarter is $0.88 on revenues of $183.98 million, and for the current fiscal year, it is $3.65 on revenues of $738.08 million [7] - The Transportation - Shipping industry, to which International Seaways belongs, is currently in the bottom 11% of the Zacks industries, indicating potential challenges ahead [8] Group 3 - Ahead of the earnings release, the estimate revisions trend for International Seaways was unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

P10, Inc. (PX) came out with quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.76%. A quarter ago, it was expected that this company would post earnings of $0.26 per share when it actually produced earnings of $0.30, delivering a surprise of 15.38%.Over the last four quarters, the company has surp ...

InfuSystems Holdings, Inc. (INFU) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.04, delivering a surprise of -50%.Over the last four quarters, the company ...